- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05327114
Étude d'efficacité et d'innocuité du nipocalimab chez les adultes atteints de polyneuropathie démyélinisante inflammatoire chronique (PDIC)
Étude de phase 2/3, en plusieurs étapes, multicentrique, randomisée, en double aveugle, contrôlée par placebo et en groupes parallèles pour évaluer l'efficacité et l'innocuité du nipocalimab administré aux adultes atteints de polyneuropathie démyélinisante inflammatoire chronique (PDIC)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- Phase 3
Accès étendu
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Berlin, Allemagne, 13347
- Actif, ne recrute pas
- Judisches Krankenhaus Berlin
-
Bochum, Allemagne, 44791
- Complété
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Allemagne, 6120
- Actif, ne recrute pas
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Allemagne, 30625
- Actif, ne recrute pas
- Medizinische Hochschule Hannover
-
Leipzig, Allemagne, 4103
- Complété
- Universitaetsklinikum Leipzig
-
Potsdam, Allemagne, 14471
- Complété
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Buenos Aires, Argentine, C1199ABB
- Actif, ne recrute pas
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentine, C1428AQK
- Recrutement
- Instituto Fleni
-
Buenos Aires, Argentine, C1428
- Complété
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentine, 2900
- Recrutement
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australie, 3004
- Complété
- The Alfred Hospital
-
Parkwood, Australie, 4215
- Complété
- Gold Coast University Hospital
-
-
-
-
-
Ottawa, Canada, K1N 6N5
- Recrutement
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Beijing, Chine, 100191
- Complété
- Peking University Third Hospital
-
Beijing, Chine, 100034
- Complété
- Peking University First Hospital
-
Beijing, Chine, 100053
- Actif, ne recrute pas
- Xuanwu Hospital ,Capital Medical University
-
Beijing, Chine, 100070
- Actif, ne recrute pas
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, Chine, 130021
- Actif, ne recrute pas
- The First Hospital of Jilin University
-
Changsha, Chine, 410008
- Complété
- Xiangya Hospital Central South University
-
Changsha, Chine, 410008
- Actif, ne recrute pas
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, Chine, 610072
- Complété
- Sichuan Provincial Peoples Hospital
-
Chifeng, Chine, 024000
- Complété
- Chifeng Municipal Hospital
-
Fuzhou, Chine, 350001
- Actif, ne recrute pas
- Fujian Medical University Union Hospital
-
Guangzhou, Chine, 510080
- Actif, ne recrute pas
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Chine, 250012
- Actif, ne recrute pas
- Qilu Hospital of Shandong University
-
Jinan, Chine, 250014
- Complété
- Qianfoshan hospital of Shandong Province
-
Nanchang, Chine, 330006
- Actif, ne recrute pas
- The First Affiliated Hospital of NanChang University
-
Shanghai, Chine, 200336
- Complété
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, Chine, 200040
- Actif, ne recrute pas
- Huashan Hospital Fudan University
-
Wuhan, Chine, 430023
- Complété
- Renmin Hospital of Wuhan University
-
Xi'an, Chine, 710032
- Complété
- Tangdu hospital the Fourth Military Medical
-
Xi'an, Chine, 710075
- Actif, ne recrute pas
- Xi 'an GaoXin Hospital
-
-
-
-
-
Floridablanca, Colombie, 681004
- Complété
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Colombie, 50021
- Actif, ne recrute pas
- Instituto Neurológico de Colombia
-
-
-
-
-
Seoul, Corée du Sud, 05030
- Complété
- Konkuk University Medical Center
-
Seoul, Corée du Sud, 02447
- Complété
- Kyunghee University Medical Center
-
Seoul, Corée du Sud, 135-710
- Complété
- Samsung Medical Center
-
-
-
-
-
Alicante, Espagne, 03010
- Actif, ne recrute pas
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Espagne, 8035
- Complété
- Hosp Univ Vall D Hebron
-
Bilbao, Espagne, 48013
- Actif, ne recrute pas
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Espagne, 20014
- Complété
- Hosp. Univ. Donostia
-
Madrid, Espagne, 28040
- Complété
- Hosp. Clinico San Carlos
-
Seville, Espagne, 41009
- Actif, ne recrute pas
- Hosp. Virgen Macarena
-
-
-
-
-
Bordeaux, France, 33000
- Complété
- CHU Bordeaux
-
Bron, France, 69699
- Complété
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, France, 94270
- Actif, ne recrute pas
- Hopital de Bicetre
-
Marseille, France, 13385
- Actif, ne recrute pas
- Hopital de la Timone
-
Nice, France, 06000
- Actif, ne recrute pas
- Hopital PASTEUR
-
Nîmes, France, 30029
- Actif, ne recrute pas
- CHU Nimes Hopital Caremeau
-
Paris, France, 75013
- Complété
- Hopital de la Pitie Salpetriere
-
Paris, France, 75019
- Complété
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, France, 67200
- Actif, ne recrute pas
- CHRU Strasbourg
-
-
-
-
-
Athens, Grèce, 12462
- Recrutement
- Attikon General Hospital of Athens
-
Athens, Grèce, 11527
- Complété
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Grèce, 26504
- Complété
- Patras University Hospital
-
Thessaloniki, Grèce, 54636
- Recrutement
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Catania, Italie, 95123
- Complété
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italie, 16132
- Complété
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italie, 20144
- Complété
- Casa di Cura del Policlinico
-
Milan, Italie, 20133
- Complété
- Istituto Neurologico Carlo Besta
-
Naples, Italie, 80131
- Actif, ne recrute pas
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italie, 10043
- Complété
- Aou San Luigi Gonzaga
-
Pavia, Italie, 27100
- Complété
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italie, 00168
- Complété
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italie, 20086
- Complété
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japon, 070-0901
- Actif, ne recrute pas
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japon, 113 8519
- Actif, ne recrute pas
- Institute of Science Tokyo Hospital
-
Chiba, Japon, 260-8677
- Complété
- Chiba University Hospital
-
Hamamatsu, Japon, 430-8558
- Actif, ne recrute pas
- Seirei Hamamatsu General Hospital
-
Isehara, Japon, 259-1193
- Actif, ne recrute pas
- Tokai University Hospital
-
Kobe, Japon, 650 0047
- Complété
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japon, 187-8551
- Actif, ne recrute pas
- National Center of Neurology and Psychiatry
-
Koshigaya, Japon, 343-8555
- Actif, ne recrute pas
- Saitama Medical Center
-
Kumamoto, Japon, 860-8556
- Complété
- Kumamoto University Hospital
-
Nagoya, Japon, 466-8560
- Actif, ne recrute pas
- Nagoya University Hospital
-
Nagoya, Japon, 455-8530
- Actif, ne recrute pas
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japon, 589 8511
- Complété
- Kindai University Hospital
-
Sendai, Japon, 983-8520
- Actif, ne recrute pas
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japon, 321 0293
- Complété
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japon, 162-8666
- Complété
- Tokyo Women's Medical University Hospital
-
Tenri, Japon, 632-0015
- Complété
- Tenri Hospital
-
Toon-shi, Japon, 791-0295
- Complété
- Ehime University Hospital
-
Toyama, Japon, 930-0194
- Complété
- Toyama University Hospital
-
Ube, Japon, 755-8505
- Complété
- Yamaguchi University Hospital
-
-
-
-
-
Almada, Le Portugal, 2805-267
- Actif, ne recrute pas
- Hospital Garcia de Orta
-
Braga, Le Portugal, 4710-243
- Complété
- Hospital de Braga
-
Porto, Le Portugal, 4200 319
- Actif, ne recrute pas
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Monterrey, Mexique, 64710
- Complété
- i Can Oncology Center
-
Tlalnepantla, Mexique, 54055
- Recrutement
- Clinical Research Institute S.C.
-
-
-
-
-
Chorzów, Pologne, 41 500
- Complété
- Centrum Medyczne
-
Krakow, Pologne, 30 539
- Complété
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Pologne, 20 093
- Complété
- Prywatny Gabinet Lekarski
-
Poznan, Pologne, 61 731
- Actif, ne recrute pas
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Birmingham, Royaume-Uni, B15 2TH
- Complété
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Royaume-Uni, EX2 5DW
- Complété
- Royal Devon & Exeter Hospital
-
Glasgow, Royaume-Uni, G514TF
- Actif, ne recrute pas
- NHS Greater Glasgow and Clyde
-
London, Royaume-Uni, NW3 2QG
- Complété
- Royal Free Hospital
-
Sheffield, Royaume-Uni, S10 2 JF
- Actif, ne recrute pas
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Kaohsiung City, Taïwan, 88301
- Complété
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taïwan, 100
- Actif, ne recrute pas
- National Taiwan University Hospital
-
Taipei, Taïwan, 111
- Actif, ne recrute pas
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Hradec Králové, Tchéquie, 500 05
- Actif, ne recrute pas
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Tchéquie, 708 52
- Complété
- Fakultni Nemocnice Ostrava
-
Pardubice, Tchéquie, 53203
- Complété
- Pardubicka krajska nemocnice a s
-
-
-
-
Colorado
-
Centennial, Colorado, États-Unis, 80112
- Actif, ne recrute pas
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, États-Unis, 33067
- Complété
- Healthcare Innovations Institute Inc
-
Maitland, Florida, États-Unis, 32751
- Complété
- Neurology Associates PA
-
Miami, Florida, États-Unis, 33136
- Actif, ne recrute pas
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30912
- Complété
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Complété
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Complété
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Complété
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, États-Unis, 48073
- Complété
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64128
- Complété
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, États-Unis, 10032
- Complété
- The Neurological Institute of New York
-
Patchogue, New York, États-Unis, 11772
- Complété
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Complété
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Actif, ne recrute pas
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, États-Unis, 78756
- Complété
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53215
- Actif, ne recrute pas
- Advocate Health - Aurora St. Luke's Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Autres noms:
|
|
Comparateur placebo: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Délai: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Délai: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Délai: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Délai: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Délai: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Délai: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Délai: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Délai: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Délai: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Délai: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Délai: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Délai: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Délai: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Délai: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Délai: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Délai: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Délai: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Délai: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Processus pathologiques
- Maladies neuromusculaires
- Maladie chronique
- Attributs de la maladie
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies du système nerveux périphérique
- Maladies auto-immunes du système nerveux
- Maladies démyélinisantes
- Polyneuropathies
- Polyradiculonévrite
- Conditions pathologiques, signes et symptômes
- Polyradiculonévrite Chronique Inflammatoire Démyélinisante
Autres numéros d'identification d'étude
- CR109195
- 80202135CDP3001 (Autre identifiant: Janssen Research & Development, LLC)
- 2021-003234-37 (Numéro EudraCT)
- 2023-508425-28-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .